Long-term safety and functional outcomes of delandistrogene moxeparvovec gene therapy in patients with Duchenne muscular dystrophy: A phase 1/2a nonrandomized trial.

MLA

Mendell, Jerry R., et al. “Long-Term Safety and Functional Outcomes of Delandistrogene Moxeparvovec Gene Therapy in Patients with Duchenne Muscular Dystrophy: A Phase 1/2a Nonrandomized Trial.” Muscle & Nerve, vol. 69, no. 1, Jan. 2024, pp. 93–98. EBSCOhost, https://doi.org/10.1002/mus.27955.

APA

Mendell, J. R., Sahenk, Z., Lehman, K. J., Lowes, L. P., Reash, N. F., Iammarino, M. A., Alfano, L. N., Lewis, S., Church, K., Shell, R., Potter, R. A., Griffin, D. A., Hogan, M., Wang, S., Mason, S., Darton, E., & Rodino-Klapac, L. R. (2024). Long-term safety and functional outcomes of delandistrogene moxeparvovec gene therapy in patients with Duchenne muscular dystrophy: A phase 1/2a nonrandomized trial. Muscle & Nerve, 69(1), 93–98. https://doi.org/10.1002/mus.27955

Chicago

Mendell, Jerry R, Zarife Sahenk, Kelly J Lehman, Linda P Lowes, Natalie F Reash, Megan A Iammarino, Lindsay N Alfano, et al. 2024. “Long-Term Safety and Functional Outcomes of Delandistrogene Moxeparvovec Gene Therapy in Patients with Duchenne Muscular Dystrophy: A Phase 1/2a Nonrandomized Trial.” Muscle & Nerve 69 (1): 93–98. doi:10.1002/mus.27955.